23

Oct2018

Welcome PDCI New Hires!

Recognizing the increasing demand for PDCI expertise and the growing needs of our clients, we are proud to announce the addition of new staff in our Health Technology Assessment (HTA) and Reimbursement Strategy Teams. Background Our vision at PDCI is to be the most trusted and valued pricing and reimbursement strategic partner. ... Read More

22

May2018

Join PDCI at the 4th Annual Canadian Institute Pharma Symposium & Save 10% off Registration

PDCI Market Access is delighted to participate in the 4th Annual Canadian Institute’s Pharma Symposium. The Pharma Symposium brings together leading stakeholders from pharmaceutical manufacturers, public/private payers, agencies, regulatory bodies and patient groups to analyze the key issues facing the industry in today’s complex environment. Participants will gain insights as ... Read More

01

Feb2018

NEW PDCI Report finds Health Canada significantly overstates benefits & underestimates negative impact of its proposed regulatory amendments

On January 29, 2018, PDCI released a report critically evaluating Health Canada’s plan to change how patented medicine prices are regulated in Canada. PDCI’s report - entitled Proposed Amendments to the Patented Medicines Regulations: A Critical Appraisal of the Cost-Benefit Analysis – includes perspectives on the Regulatory Impact Assessment Statement ... Read More

20

Dec2017

Happy Holidays from PDCI Market Access

05

Dec2017

Health Canada releases proposed PMPRB Price Regulations – The Charge of the Price Brigade

The mandatory public consultation process must be a tiresome inconvenience for Health Canada policy makers.  At least that’s the perception from the release of its proposed amendments to the Patented Medicines Regulations (Regulations) and the accompanying Regulatory Impact Assessment Statement (RIAS) published in Canada Gazette Part I last week.  Why ... Read More

04

Dec2017

PDCI Webinar: Proposed Amendments to Patented Medicines Regulations – What Patentees Need to Know

Join us for a webinar on Dec 06, 2017 at 2:00 PM EST. Register now! Join PDCI’s Founder and Principal Consultant, Neil Palmer on this industry only webinar as he discusses the proposed amendments to the Patented Medicines Regulations as published in Canada Gazette Part 1 on December 2, 2017. What ... Read More

01

Dec2017

Proposed Amendments to Patented Medicines Regulations Announced

Proposed regulatory text of amendments to the Patented Medicines Regulations is published by the Governor-in-Council in Canada Gazette Part I (CG1) on December 2, 2017.  Interested persons may submit comments on the proposed regulations within 75 days of publication in CG1 (by ... Read More

31

Oct2017

PDCI is excited to announce another great addition to the PDCI team: John-Paul Dowson, Director, Reimbursement Strategy

It is with great pleasure to announce after several months of a successful strategic partnership with Roubaix Strategies Inc. (RSI), John-Paul Dowson is formally joining the PDCI team as our new Director of Reimbursement Strategy. John-Paul brings more than 20 years of senior experience working in the health and pharmaceutical sectors. ... Read More

30

Oct2017

PDCI Welcomes Jennifer Haig as Manager, HTA and Health Economics

We are pleased to announce that effective October 30, 2017 Jennifer Haig has joined PDCI Market Access Inc. as Manager, HTA and Health Economics. Jen joins our growing HTA team and brings extensive experience with Pharmacoeconomic and Budget Impact modelling. Prior to joining PDCI, Jen was a market access and health ... Read More